Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy
International Journal of Gynecology & Obstetrics · 2024-10 · 167 (1) · 80-87
DOI: 10.1002/ijgo.15609 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 15.05.2024. Verfasst von Szu-Ting Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Bevacizumab, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program, Taipei Veterans General Hospital.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Bevacizumab serves as an effective treatment in cervical cancer patients with metastatic, recurrent, or advanced disease. However, gastrointestinal (GI)/genitourinary (GU) toxicities have been observed after bevacizumab treatment. Radiotherapy (RT) is the mainstay of treatment of cervical cancer.
Objectives
To investigate the risk of GI/GU toxicities with bevacizumab plus RT compared with RT alone in cervical cancer patients. Search Strategy In this meta‐analysis, PubMed, Embase, Web of Science, and Cochrane databases were searched from inception to September 25, 2022. Selection Criteria Cohort studies evaluating the association between bevacizumab and GI/GU fistula or perforation in irradiated metastatic, recurrent, or advanced cervical cancer patients. Data Collection and Analysis Results are expressed as odds ratios (OR) with 95% confidence intervals (CI). The inconsistency test ( I 2 ) was used to assess heterogeneity. Egger's regression test with a two‐tailed P value was used to evaluate publication bias. Main Results Four cohort studies met the inclusion criteria with a total of 597 women included. There was a significant association between GI fistula/perforation and GU fistula/perforation in irradiated cervical cancer patients receiving bevacizumab (OR 4.03 [95% CI: 1.76–9.20] and OR 4.71 [95% CI: 1.51–14.70], respectively).
Conclusions
The bevacizumab‐containing regimen was associated with an increased risk of GI or GU toxicities in cervical cancer individuals undergoing pelvic RT. These results suggest the bevacizumab‐associated benefits and risk should be better weighted to reach an optimal treatment strategy. Further investigation on optimal dosage and timing of bevacizumab and RT is vital to minimize the adverse events and maximize the benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Medical Imaging and Intervention, Tucheng Hospital, New Taipei City, Taiwan.
- Department of Urban Industrial Management and Marketing, University of Taipei, Taipei, Taiwan.
- Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Peng-Hui Wang
Förderung
- Ministry of Science and Technology, Taiwan
- Yin Shu-Tien Foundation Taipei Veterans General Hospital-National Yang Ming Chiao Tung University Excellent Physician Scientists Cultivation Program
- Taipei Veterans General Hospital
- Female Cancer Foundation
- National Science and Technology Council
Zitieren
APA
Yang, S. T., Liu, H. H., Liu, C. H., Wang, L. W., & Wang, P. H. (2024). Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy. International Journal of Gynecology & Obstetrics, 167(1), 80-87. https://doi.org/10.1002/ijgo.15609
Vancouver
Yang ST, Liu HH, Liu CH, Wang LW, Wang PH. Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy. International Journal of Gynecology & Obstetrics. 2024;167(1):80-87. doi:10.1002/ijgo.15609
BibTeX
@article{Yang2024,
author = {Yang, Szu-Ting and Liu, Hung-Hsien and Liu, Chia-Hao and Wang, Liang-Wei and Wang, Peng-Hui},
title = {Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy},
journal = {International Journal of Gynecology & Obstetrics},
year = {2024},
volume = {167},
number = {1},
pages = {80--87},
doi = {10.1002/ijgo.15609}
}
EUVIMED